Skip to content

Study · Randomized controlled trial · 2016

8 results

Influences of teriparatide administration on marrow fat content in postmenopausal osteopenic women using MR spectroscopy.

Yang Y, Luo X, Xie X, Yan F, Chen G, Zhao W, Jiang Z, Fang C, Shen J

Climacteric : the journal of the International Menopause Society8 Jan 2016Cited by 38 (Europe PMC)

PMID26744910 (opens in a new tab)DOI10.3109/13697137.2015.1126576 (opens in a new tab)PepBankPUB-26744910
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In postmenopausal osteopenic women, lumbar spine BMD increased 3.51% from baseline with teriparatide at 12 months.

    In plain wordsIn women with osteopenia, spine bone density increased from baseline with teriparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseLumbar spine BMD
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    BMD change
    3.51%
    lumbar spine at 12 months

    Source sentences

    Summary
    Results At 12 months, mean percentage changes in BMD from baseline were 3.51%, 2.21% and 1.80% at lumbar spine, total hip and femoral neck for the teriparatide group, respectively.
    1 context sentence
    Summary · context
    Methods Postmenopausal osteopenic women were randomly assigned to receive teriparatide or placebo for 12 months.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In postmenopausal osteopenic women, total hip BMD increased 2.21% from baseline with teriparatide at 12 months.

    In plain wordsIn women with osteopenia, total hip bone density increased from baseline with teriparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTotal hip BMD
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    BMD change
    2.21%
    total hip at 12 months

    Source sentences

    Summary
    Results At 12 months, mean percentage changes in BMD from baseline were 3.51%, 2.21% and 1.80% at lumbar spine, total hip and femoral neck for the teriparatide group, respectively.
    1 context sentence
    Summary · context
    Methods Postmenopausal osteopenic women were randomly assigned to receive teriparatide or placebo for 12 months.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In postmenopausal osteopenic women, femoral neck BMD increased 1.80% from baseline with teriparatide at 12 months.

    In plain wordsIn women with osteopenia, femoral neck bone density increased from baseline with teriparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseFemoral neck BMD
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    BMD change
    1.8%
    femoral neck at 12 months

    Source sentences

    Summary
    Results At 12 months, mean percentage changes in BMD from baseline were 3.51%, 2.21% and 1.80% at lumbar spine, total hip and femoral neck for the teriparatide group, respectively.
    1 context sentence
    Summary · context
    Methods Postmenopausal osteopenic women were randomly assigned to receive teriparatide or placebo for 12 months.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In postmenopausal osteopenic women, teriparatide reduced marrow fat fraction by 3.54% from baseline at 6 months.

    In plain wordsIn women with osteopenia, teriparatide reduced marrow fat from baseline at 6 months.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseMarrow fat fraction at 6 months
    Study

    n: not reported in source

    Outcome group
    Body composition · Musculoskeletal
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    MFF change from baseline
    −3.54%
    teriparatide group at 6 months

    Source sentences

    Summary
    Relative to baseline conditions, teriparatide reduced MFF (-3.54% at 6 months; -5.87% at 12 months, all p < 0.01).
    1 context sentence
    Summary · context
    Methods Postmenopausal osteopenic women were randomly assigned to receive teriparatide or placebo for 12 months.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In postmenopausal osteopenic women, teriparatide reduced marrow fat fraction by 5.87% from baseline at 12 months.

    In plain wordsIn women with osteopenia, teriparatide reduced marrow fat from baseline at 12 months.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseMarrow fat fraction at 12 months
    Study

    n: not reported in source

    Outcome group
    Body composition · Musculoskeletal
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Measurements

    MFF change from baseline
    −5.87%
    teriparatide group at 12 months

    Source sentences

    Summary
    Relative to baseline conditions, teriparatide reduced MFF (-3.54% at 6 months; -5.87% at 12 months, all p < 0.01).
    1 context sentence
    Summary · context
    Methods Postmenopausal osteopenic women were randomly assigned to receive teriparatide or placebo for 12 months.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In postmenopausal osteopenic women, marrow fat fraction differed between teriparatide and placebo at 6 months, with teriparatide reducing marrow fat.

    In plain wordsIn women with osteopenia, teriparatide reduced marrow fat compared with placebo at 6 months.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseMarrow fat fraction versus placebo
    Study

    n: not reported in source

    Comparator
    placebo
    Outcome group
    Body composition · Musculoskeletal
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    A significant difference in MFF, but not BMD, was first detected at 6 months (p = 0.012) between groups.
    2 context sentences
    Summary · context
    Relative to baseline conditions, teriparatide reduced MFF (-3.54% at 6 months; -5.87% at 12 months, all p < 0.01).
    Summary · context
    Methods Postmenopausal osteopenic women were randomly assigned to receive teriparatide or placebo for 12 months.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In postmenopausal osteopenic women, BMD did not differ significantly between teriparatide and placebo at 6 months.

    In plain wordsIn women with osteopenia, bone density did not differ significantly between teriparatide and placebo at 6 months.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeBMD versus placebo at 6 months
    Study

    n: not reported in source

    Comparator
    placebo
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    A significant difference in MFF, but not BMD, was first detected at 6 months (p = 0.012) between groups.
    1 context sentence
    Summary · context
    Methods Postmenopausal osteopenic women were randomly assigned to receive teriparatide or placebo for 12 months.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In postmenopausal osteopenic women, teriparatide did not alter abdominal fat composition.

    In plain wordsIn women with osteopenia, teriparatide did not change abdominal fat composition.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeAbdominal fat composition
    Study

    n: not reported in source

    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    Dose not stated · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    Teriparatide treatment did not alter abdominal fat composition.
    1 context sentence
    Summary · context
    Methods Postmenopausal osteopenic women were randomly assigned to receive teriparatide or placebo for 12 months.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.